F S&P 500
5,074.75 +12.50 (+0.25%) F Dow Jones
38,068.00 +78.00 (+0.21%) F Nasdaq
17,711.25 +52.75 (+0.30%) E-mini Russell 2000 Index Futur
1,964.10 +2.10 (+0.11%) Petróleo
82.31 -0.38 (-0.46%) Oro
2,397.20 +8.80 (+0.37%)
iCAD, Inc. (ICAD)
Fuera de horario:
iCAD, Inc.
98 Spit Brook Road
Suite 100
Nashua, NH 03062
United States
603 882 5200
https://www.icadmed.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 67
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Dana R. Brown | President, CEO & Executive Chair | N/D | N/D | 1965 |
| Mr. Jonathan Go | Chief Technology Officer | 351.89k | N/D | 1963 |
| Mr. Eric Lonnqvist | Chief Financial Officer | N/D | N/D | N/D |
| Ms. Michelle Strong | Chief Operations Officer | N/D | N/D | N/D |
| Ms. Annette L. Heroux | Vice President of Administration | 174.9k | N/D | 1957 |
| Mr. Anthony Takazawa | Director of Investor Relations | N/D | N/D | N/D |
| Brian Testa | Chief People Officer | N/D | N/D | N/D |
| Mr. Bill Keyes | Senior VP of Global Sales Operations | N/D | N/D | N/D |
| Mr. Vasu Avadhanula | Chief Product Officer | N/D | N/D | N/D |
| Mr. Peter Graham | Senior VP of North American Sales | N/D | N/D | N/D |
Descripción
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Gestión corporativa
La calificación ISS Governance QuickScore de iCAD, Inc. a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 9; Junta: 5; Derechos del accionista: 3; Compensación: 6.
